Abstract 2323
Background
It is well documented that survival of CRC is dependent on early diagnosis. In England, the Department of Health’s cancer policy states that patients with symptoms of suspected cancer must be seen and assessed by the specialist team within 2 weeks of a referral by their General Practitioner (GP). The traditional 2 week wait (2ww) referral route involves these patients being seen in clinic within 2 weeks, where they are assessed and an investigation is booked, taking up to 4 weeks for first investigation and diagnosis. We have introduced a novel Straight to Test / CTAP for these patients, which rationalises the patient journey, ensuring that the patient has the right test first time, without delay.
Methods
Our service is a Consultant Nurse led Straight to Test / CTAP. All 2ww patients referred by the GP with suspected CRC are assessed via the CTAP. Upon receipt of the electronic referral from their GP, a colorectal assessment is carried out via telephone within 48 hours of referral by the Consultant nurse or a member or her specialist nursing team. The patient is then triaged for the most appropriate investigation, according to a protocol, which is then booked within 2 weeks of the GPs referral.
Results
The CTAP has been running now for 5 years with over 4000 patients being assessed via this route. In 2017 & 2018 the cancer yield from our service was 4% which matches that of traditional out-patient assessments routes. However we were able to reduce the patient pathway by 10 days by the introduction of the CTAP. 70% of patients had an endoscopy procedure as their first investigation and 28% had a radiological investigation (usually CT Colonography). 90% of patients had their diagnosis or given the all clear by day 14.
Conclusions
This pathway has significantly shortened the patient’s pathway and time diagnosis for our patients, meaning that those patients with CRC are diagnosed by day 14. Patients with other pathologies are also diagnosed quicker and those patients with no serious pathology are reassured and discharged back to their GP We have managed to reduce waiting times from referral to diagnosis and to ensure all patients on the 2ww pathway have a more streamline patient focused experience, avoiding unnecessary hospital visits.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract